Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;6(4):140-144.
doi: 10.1016/j.prnil.2018.01.002. Epub 2018 Feb 2.

Comparative quality-adjusted survival analysis between radiation therapy alone and radiation with androgen deprivation therapy in patients with locally advanced prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 85-31 with novel decision analysis methods

Soyeon Ahn  1 , Minjung Lee  2 , Chang Wook Jeong  3
Affiliations

Comparative quality-adjusted survival analysis between radiation therapy alone and radiation with androgen deprivation therapy in patients with locally advanced prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 85-31 with novel decision analysis methods

Soyeon Ahn et al. Prostate Int. 2018 Dec.

Abstract

Background: Androgen deprivation therapy in addition to radiation therapy (RT + ADT) has shown benefits in local control and progression-free survival compared with RT alone for patients with locally advanced prostate cancer in Radiation Therapy Oncology Group 85-31. However, the survival gain may be diluted with increased toxicity of ADT. The aim of the study is to compare quality-adjusted life years (QALYs) values between two groups.

Methods: We developed "quality-adjusted survival analysis using duration" (QASAD) and "quality-adjusted survival analysis using probability" (QASAP) to estimate the quality-adjusted survival time. The QASAD uses the median duration in each health state to weight the utilities, whereas the QASAP uses the proportional probability of being in each state for weighting. The survival and complication rates were reconstructed based on published Kaplan-Meier survival curves, and the utility values for states were obtained from the previous literature.

Results: QALYs values for RT + ADT were generally higher than those for RT. The QASAD resulted in a QALY value of 4.93 [95% bootstrapped confidence interval (CI) = 4.12-5.71] for RT and of 5.60 (95% CI = 4.30-6.48) for RT + ADT. QASAP resulted in a QALY value of 4.85 (95% CI = 4.16-5.39) for RT and 4.96 (95% CI = 3.73-5.78) for RT + ADT.

Conclusions: We showed that RT + ADT provided slightly better quality-adjusted survival outcome than RT alone. The QASAD and QASAP methods may help the decision of optimal treatment balancing between survival gain and unfavorable quality of life.

Keywords: Decision support techniques; Quality of life; Quality-adjusted life years; Quality-adjusted survival analysis; Survival analysis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Probabilistic sensitivity analyses. (A) Distribution of the QALY values obtained from quality-adjusted survival analysis using duration (QASAD). (B) Distribution of the QALY values obtained from quality-adjusted survival analysis using probability (QASAP).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lawton C.A., Winter K., Murray K., Machtay M., Mesic J.B., Hanks G.E. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937–946. - PubMed
    1. Pilepich M.V., Winter K., John M.J., Mesic J.B., Sause W., Rubin P. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243–1252. - PubMed
    1. Lawton C.A.F., Lin X., Hanks G.E., Lepor H., Grignon D.J., Brereton H.D. Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017;98:296–303. - PMC - PubMed
    1. Konski A., Sherman E., Krahn M., Bremner K., Beck J.R., Watkins-Bruner D. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10) Int J Radiat Oncol Biol Phys. 2005;63:788–794. - PubMed
    1. Konski A., Watkins-Bruner D., Brereton H., Feigenberg S., Hanks G. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer. 2006;106:51–57. - PubMed